What Leading Pharma does

Leading Pharma, LLC is a privately held U.S. generic pharmaceutical company founded in 2014 and headquartered at 3 Oak Road, Fairfield, New Jersey. The company develops, manufactures, and distributes oral solid dose (OSD) generic pharmaceutical products across multiple therapeutic areas, with a growing share of products manufactured at its own FDA-approved, cGMP-compliant facility. As of recent data, the company employs more than 200 people operating from a 53,000 square foot facility containing more than 30 manufacturing suites capable of producing more than 2.5 billion tablets annually. The company also partners with FDA-compliant global manufacturers to broaden its portfolio beyond in-house capacity.

The company's revenue model combines direct sales of generic pharmaceutical products with partnership, licensing, and authorized-generics arrangements. Products are sold to institutional buyers including drugstore chains, pharmaceutical wholesalers and distributors, mass merchandisers, government agencies, and managed care accounts. The business development team, led by Chief Business Officer Brian Shapiro, actively explores ANDA/NDA acquisitions, finished-dosage partnerships, and API licensing opportunities to expand the portfolio. Front-end sales and marketing services are offered to partners to maximize market share of distributed products.

Regulatory credentials form a core part of the value proposition: the facility is FDA-approved and cGMP compliant, DSCSA compliant, and holds a DEA license for the manufacture and importation of Schedule III–V controlled substances. The company was founded by Ronald Gold, a serial entrepreneur who previously founded Rising Pharmaceuticals in 1992 and oversaw its 2010 sale to Aceto Corporation, bringing decades of generic-pharma operating experience to the management team. In January 2018, Leading Pharma raised $40 million in growth equity led by Signet Healthcare Partners, with participation from Cane Investment Partners and Crestline.

Name

Leading Pharma

Legal name

Leading Pharma, LLC

Website

https://leadingpharma.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

Leading Pharma is a privately held Fairfield, NJ-based generic pharmaceutical manufacturer founded in 2014 that develops, produces, and distributes oral solid dose generics and authorized generics to drugstore chains, wholesalers, distributors, government agencies, and managed care accounts.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Generic pharmaceuticals
• Oral solid dose manufacturing
• Authorized generics
• ANDA licensing
• Pharmaceutical contract manufacturing

Headquarters

HQ city

Fairfield

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Infrastructure, Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Product Sales: Leading Pharma develops, manufactures and distributes safe and effective generic pharmaceutical products. Revenue is generated through the sale of generic medications across various therapeutic areas to wholesalers, distributors, drugstore chains, mass merchandisers, government agencies and managed care accounts.
2. Partnership and Licensing: The company explores partnership and licensing opportunities in finished dosage, active pharmaceutical ingredients (APIs), and authorized generics. They also consider ANDA/NDA divestiture opportunities, generating revenue through licensing arrangements.
3. Authorized Generics: Development and distribution of authorized generic pharmaceutical products under the Leading Pharma label.
4. Front-End Sales and Marketing Services: Complete front-end sales and marketing services provided to partners to ensure maximum market share for distributed products.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels2 records

Core offering

Leading Pharma develops, manufactures, and distributes safe and effective generic pharmaceutical products across a wide range of therapeutic areas, offering lower-cost alternatives to brand-name medicines. The company operates a 53,000 sq ft FDA-approved, cGMP-compliant oral solid dose manufacturing facility in Fairfield, NJ with capacity for more than 2.5 billion tablets annually, supported by in-house R&D, quality assurance, packaging, warehousing, and shipping. Complementary offerings include authorized generics, ANDA/NDA divestiture opportunities, partnership and licensing of finished dosage and APIs, and complete front-end sales and marketing services for institutional buyers.

Product overview

Leading Pharma is a privately held pharmaceutical company that manufactures, markets, and distributes generic pharmaceutical products. The company operates as a single unified offering focused on generic pharmaceuticals across therapeutic areas, combining in-house U.S. manufacturing with global partnerships. The product portfolio includes: (1) Generic Pharmaceutical Products as the core offering, supplemented by (2) Authorized Generics for brand-name re-releases, (3) Partnership & Licensing services for business development, (4) Manufacturing Services from their FDA-approved 53,000 sq ft facility, (5) Front-End Sales & Marketing for distribution, and (6) ANDA/NDA Divestiture opportunities. These components work together to deliver a vertically integrated approach from product development through customer distribution.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Pharmaceutical Products Safe and effective generic pharmaceutical products across a wide range of therapeutic areas, offering consumers lower-cost generic alternatives to brand-name medicines. The portfolio includes various oral solid dose dosage forms manufactured in-house at the Fairfield, NJ facility and through global FDA-compliant partners, sold to drugstore chains, wholesalers, distributors, mass merchandisers, government agencies, and managed care accounts.
• Authorized Generics Brand-name drugs re-released and distributed as generics under the Leading Pharma label, providing lower-cost alternatives through the company's U.S. distribution network to institutional buyers.
• Manufacturing Services U.S.-based FDA-approved contract manufacturing of oral solid dose products under cGMP and DSCSA compliance. The 53,000 sq ft facility contains more than 30 manufacturing suites for blending, compression, drying, and coating, with capacity exceeding 2.5 billion tablets per year, supporting partners and the company's own product portfolio.
• Front-End Sales & Marketing Complete front-end sales and marketing services provided to ensure maximum market share for distributed products, serving drugstore chains, distributors, wholesalers, mass merchandisers, government agencies, and managed care accounts.
• Partnership & Licensing Business development offering for partnership and licensing opportunities in finished dosage pharmaceuticals, active pharmaceutical ingredients (APIs), and authorized generics. Each proposal undergoes comprehensive analysis to ensure maximum impact upon launch, with partners gaining access to Leading Pharma's FDA-compliant U.S. manufacturing and distribution.
• ANDA/NDA Divestiture Acquisition opportunities for Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA) from manufacturers seeking to divest products, allowing the acquirer to leverage Leading Pharma's U.S. manufacturing, distribution, and sales capabilities.

Quantifiable outcome

• More than 2.5 billion tablets per year production capacity
• +2 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• FDA-Compliant Global SupplierscoreStrategic or Co-development PartnerLeading Pharma partners with FDA-compliant suppliers and manufacturers around the globe to bring a wide range of quality, affordable medications across many dosage forms and therapeutic areas to its customers in the U.S.A. under the Leading Pharma label.

Scale indicators5 records

Direct peers

• Hikma Pharmaceuticals: Hikma is a U.S.- and MENA-focused generic pharmaceutical manufacturer with branded and injectable segments. It is highly comparable because it competes in oral solid dose generics, sells through U.S. drugstore chains and institutional channels, and Leading Pharma's VP Sales Elizabeth Guerrero previously held a Director role at Hikma.
• Amneal Pharmaceuticals: Amneal is a U.S.-headquartered generic and specialty pharmaceutical manufacturer with significant oral solid dose manufacturing capacity. Comparable because of its focus on affordable generics across multiple therapeutic areas and U.S.-based manufacturing footprint serving similar institutional and retail buyers.
• Endo International: Endo operates a U.S. generics and specialty branded business focused on oral solid and sterile injectable products. Comparable because of overlapping therapeutic coverage, retail and institutional channel mix, and exposure to U.S. generic pricing dynamics.
• Lupin Pharmaceuticals: Lupin is a global generic manufacturer with substantial U.S. operations and oral solid dose capabilities. Comparable because of similar product mix in affordable generics, ANDA-driven portfolio growth, and parallel U.S. sales channels including drugstore chains and managed care.
• Aurobindo Pharma: Aurobindo is one of the largest Indian generic manufacturers with significant U.S. oral solid dose presence. Comparable because of its broad therapeutic-area generic portfolio, ANDA pipeline, and reliance on U.S. drugstore, wholesale, and managed care distribution.
• Apotex: Apotex is a privately held Canadian generic pharmaceutical manufacturer with U.S. commercial operations. Comparable because of its private ownership structure, broad generic portfolio, and similar focus on affordable oral solid dose products across multiple therapeutic areas.

Emerging players

• Padagis: Padagis (formerly Perrigo's generics business) is a U.S. specialty generics manufacturer with topical and oral dose products. Comparable as a smaller, focused generic manufacturer selling through similar U.S. drugstore, wholesale, and managed care channels.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with a vast U.S. oral solid dose portfolio. Comparable as the dominant incumbent competing head-to-head in nearly every generic therapeutic area Leading Pharma serves, though at vastly larger scale.
• Viatris: Viatris (formed from Mylan/Upjohn) is a global generics and biosimilars major with deep U.S. generic exposure. Comparable as a direct U.S. generic competitor across multiple therapeutic areas, distribution channels, and buyer segments, but with global reach Leading Pharma lacks.
• Sandoz: Sandoz is the Novartis generics and biosimilars division and one of the top global generic players. Comparable as a broad incumbent competing in U.S. oral solid dose generics through the same drugstore, wholesale, and managed care channels.

Market position

Strengths4 records

Weaknesses4 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leading Pharma